Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis

Journal of Neuroimmunology

Volumn 262, Issue 1-2, 2013, Pages 113-120

  Fialová, Lenka ^a   Bartos, Ales ^a,c,d   Švarcová, Jana ^a,b   Zimova, Denisa ^a,c   Kotoucova, Jolana ^a,c   Malbohan, Ivan ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Antibody; Cerebrospinal fluid; Clinically isolated syndrome; Light neurofilament subunit; Multiple sclerosis; Serum

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN G ANTIBODY; NEUROFIBRIL ANTIBODY; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; RELAPSE; REMISSION;

ANTIBODY; CEREBROSPINAL FLUID; CLINICALLY ISOLATED SYNDROME; LIGHT NEUROFILAMENT SUBUNIT; MULTIPLE SCLEROSIS; SERUM;

ADULT; AUTOANTIBODIES; AXONS; BIOLOGICAL MARKERS; DEMYELINATING DISEASES; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; PRODROMAL SYMPTOMS; YOUNG ADULT;

EID: 84884161962     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.06.010     Document Type: Article

References (54)

1. Axelsson M., Malmestrom C., Nilsson S., Haghighi S., Rosengren L., Lycke J. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J. Neurol. 2011, 258:882-888.
2. Bartos A., Fialova L., Soukupova J., Kukal J., Malbohan I., Pit'ha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J. Neurol. 2007, 254:20-25.
3. Bartos A., Fialova L., Soukupova J., Kukal J., Malbohan I., Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol. Scand. 2007, 116:100-107.
4. Bartos A., Fialova L., Svarcova J., Ripova D. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. J. Neuroimmunol. 2012, 252:100-105.
5. Beltran E., Hernandez A., Lafuente E.M., Coret F., Simo-Castello M., Bosca I., Perez-Miralles F.C., Burgal M., Casanova B. Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis. J. Neuroimmunol. 2012, 247:63-69.
6. Beyer N.H., Lueking A., Kowald A., Frederiksen J.L., Heegaard N.H. Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 2012, 242:26-32.
7. Brettschneider J., Petzold A., Junker A., Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult. Scler. 2006, 12:143-148.
8. Brettschneider J., Czerwoniak A., Senel M., Fang L., Kassubek J., Pinkhardt E., Lauda F., Kapfer T., Jesse S., Lehmensiek V., Ludolph A.C., Otto M., Tumani H. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 2010, 5:e11986.
9. Couratier P., Yi F.H., Preud'homme J.L., Clavelou P., White A., Sindou P., Vallat J.M., Jauberteau M.O. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 1998, 154:137-145.
10. de Jong D., Jansen R.W., Pijnenburg Y.A., van Geel W.J., Borm G.F., Kremer H.P., Verbeek M.M. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 2007, 78:936-938.
11. Deisenhammer F., Bartos A., Egg R., Gilhus N.E., Giovannoni G., Rauer S., Sellebjerg F. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur. J. Neurol. 2006, 13:913-922.
12. Delpech B., Lichtblau E. Immunochemical estimation of IgG and albumin in cerebrospinal fluid. Clin. Chim. Acta 1972, 37:15-23.
13. Ehling R., Lutterotti A., Wanschitz J., Khalil M., Gneiss C., Deisenhammer F., Reindl M., Berger T. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult. Scler. 2004, 10:601-606.
14. Eikelenboom M.J., Petzold A., Lazeron R.H., Silber E., Sharief M., Thompson E.J., Barkhof F., Giovannoni G., Polman C.H., Uitdehaag B.M. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003, 60:219-223.
15. Ferraro D., Simone A.M., Bedin R., Galli V., Vitetta F., Federzoni L., D'Amico R., Merelli E., Nichelli P.F., Sola P. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J. Neuroimmunol. 2013, 257:76-81.
16. Fialova L., Svarcova J., Bartos A., Ridzon P., Malbohan I., Keller O., Rusina R. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2010, 17:562-566.
17. Fialova L., Bartos A., Svarcova J., Malbohan I. Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. PLoS One 2011, 6:e27476.
18. Fialova L., Svarcova J., Bartos A., Malbohan I. Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiol. (Praha) 2012, 57:415-419.
19. Fialova L., Bartos A., Svarcova J., Zimova D., Kotoucova J. Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis. J. Neuroimmunol. 2013, 259:81-87.
20. Giovannoni G., Nath A. After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage. Neurology 2011, 76:1200-1201.
21. Huizinga R., Heijmans N., Schubert P., Gschmeissner S.T., Hart B.A., Herrmann H., Amor S. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J. Neuropathol. Exp. Neurol. 2007, 66:295-304.
22. Huizinga R., Gerritsen W., Heijmans N., Amor S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol. Dis. 2008, 32:461-470.
23. Hvaring C., Vujicic S., Aasly J.O., Feinstein D.L., White L.R., Boullerne A.I. IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 2013, 256:77-83.
24. Jonsson M., Zetterberg H., van Straaten E., Lind K., Syversen S., Edman A., Blennow K., Rosengren L., Pantoni L., Inzitari D., Wallin A. Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur. J. Neurol. 2010, 17:377-382.
25. Julien J.P., Couillard-Despres S., Meier J. Transgenic mice in the study of ALS: the role of neurofilaments. Brain Pathol. 1998, 8:759-769.
26. Kuhle J., Regeniter A., Leppert D., Mehling M., Kappos L., Lindberg R.L., Petzold A. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J. Neuroimmunol. 2010, 220:114-119.
27. Kuhle J., Leppert D., Petzold A., Regeniter A., Schindler C., Mehling M., Anthony D.C., Kappos L., Lindberg R.L. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011, 76:1206-1213.
28. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
29. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
30. Lycke J.N., Karlsson J.E., Andersen O., Rosengren L.E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1998, 64:402-404.
31. Malmestrom C., Haghighi S., Rosengren L., Andersen O., Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003, 61:1720-1725.
32. Norgren N., Rosengren L., Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003, 987:25-31.
33. Norgren N., Sundstrom P., Svenningsson A., Rosengren L., Stigbrand T., Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004, 63:1586-1590.
34. Perrot R., Eyer J. Neuronal intermediate filaments and neurodegenerative disorders. Brain Res. Bull. 2009, 80:282-295.
35. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 2005, 233:183-198.
36. Petzold A., Eikelenboom M.J., Keir G., Grant D., Lazeron R.H., Polman C.H., Uitdehaag B.M., Thompson E.J., Giovannoni G. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J. Neurol. Neurosurg. Psychiatry 2005, 76:206-211.
37. Petzold A., Altintas A., Andreoni L., Bartos A., Berthele A., Blankenstein M.A., Buee L., Castellazzi M., Cepok S., Comabella M., Constantinescu C.S., Deisenhammer F., Deniz G., Erten G., Espino M., Fainardi E., Franciotta D., Freedman M.S., Giedraitis V., Gilhus N.E., Giovannoni G., Glabinski A., Grieb P., Hartung H.P., Hemmer B., Herukka S.K., Hintzen R., Ingelsson M., Jackson S., Jacobsen S., Jafari N., Jalosinski M., Jarius S., Kapaki E., Kieseier B.C., Koel-Simmelink M.J., Kornhuber J., Kuhle J., Kurzepa J., Lalive P.H., Lannfelt L., Lehmensiek V., Lewczuk P., Livrea P., Marnetto F., Martino D., Menge T., Norgren N., Papuc E., Paraskevas G.P., Pirttila T., Rajda C., Rejdak K., Ricny J., Ripova D., Rosengren L., Ruggieri M., Schraen S., Shaw G., Sindic C., Siva A., Stigbrand T., Stonebridge I., Topcular B., Trojano M., Tumani H., Twaalfhoven H.A., Vecsei L., Van Pesch V., Vanderstichele H., Vedeler C., Verbeek M.M., Villar L.M., Weissert R., Wildemann B., Yang C., Yao K., Teunissen C.E. Neurofilament ELISA validation. J. Immunol. Methods 2010, 352:23-31.
38. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58:840-846.
39. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor. Neurol. Neurosci. 2003, 21:79-96.
40. Reynolds R., Roncaroli F., Nicholas R., Radotra B., Gveric D., Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 2011, 122:155-170.
41. Sadaba M.C., Tzartos J., Paino C., Garcia-Villanueva M., Alvarez-Cermeno J.C., Villar L.M., Esiri M.M. Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J. Neuroimmunol. 2012, 247:86-94.
42. Salzer J., Svenningsson A., Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult. Scler. 2010, 16:287-292.
43. Semra Y.K., Seidi O.A., Sharief M.K. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J. Neuroimmunol. 2002, 122:132-139.
44. Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002, 58:1372-1381.
45. Singh P., Yan J., Hull R., Read S., O'Sullivan J., Henderson R.D., Rose S., Greer J.M., McCombe P.A. Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. J. Neurol. Sci. 2011, 304:117-121.
46. Teunissen C.E., Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult. Scler. 2012, 18:552-556.
47. Teunissen C.E., Dijkstra C., Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005, 4:32-41.
48. Teunissen C.E., Iacobaeus E., Khademi M., Brundin L., Norgren N., Koel-Simmelink M.J., Schepens M., Bouwman F., Twaalfhoven H.A., Blom H.J., Jakobs C., Dijkstra C.D. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009, 72:1322-1329.
49. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., Franciotta D., Frederiksen J.L., Fleming J.O., Furlan R., Hintzen R.Q., Hughes S.G., Johnson M.H., Krasulova E., Kuhle J., Magnone M.C., Rajda C., Rejdak K., Schmidt H.K., van Pesch V., Waubant E., Wolf C., Giovannoni G., Hemmer B., Tumani H., Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
50. Tewarie P., Teunissen C.E., Dijkstra C.D., Heijnen D.A., Vogt M., Balk L., Vrenken H., Polman C.H., Killestein J. Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis. J. Neuroimmunol. 2012, 251:103-106.
51. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
52. Tumani H., Hartung H.P., Hemmer B., Teunissen C., Deisenhammer F., Giovannoni G., Zettl U.K. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 2009, 35:117-127.
53. Vyshkina T., Kalman B. Autoantibodies and neurodegeneration in multiple sclerosis. Lab. Invest. 2008, 88:796-807.
54. Zhang Y., Li X., Qiao J. Neurofilament protein light in multiple sclerosis. Zhonghua Yi Xue Za Zhi 2007, 87:2745-2749.